DFTX NEWS
businesswire.com
1d ago
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company's management team will participate in the following investor conferences and events: 25th Annual Needham Virtual Healthcare Conference Fireside Chat Date and Time: Thursday, April 16, 2026 at 3:00 PM EDT Webcast.
defenseworld.net
5d ago
Definium Therapeutics, Inc. (NASDAQ:DFTX) Given Average Rating of “Buy” by Analysts
Definium Therapeutics, Inc. (NASDAQ: DFTX - Get Free Report) has been assigned a consensus rating of "Buy" from the twelve brokerages that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, nine have issued a buy recommendation and two have issued a strong buy recommendation on the company. The
businesswire.com
Mar 31
New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), announced results from a retrospective, longitudinal study published in the Journal of Mood and Anxiety Disorders examining the real-world prevalence, incidence, and burden of GAD in the United States healthcare system from 2020 to 2023. These findings show a steadily increasing diagnosed prevalence of GAD and highlight a substantial and growing burden affecting more than 1 in 10 adults in the U.S. Together, t.
businesswire.com
Mar 30
Definium Therapeutics Announces New Employee Inducement Grants
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 55,580 common shares of the Company (the "Options") with effective grant dates of March 16, 202.
defenseworld.net
Mar 29
Definium Therapeutics, Inc. (NASDAQ:DFTX) Short Interest Update
Definium Therapeutics, Inc. (NASDAQ: DFTX - Get Free Report) was the recipient of a significant drop in short interest in the month of March. As of March 13th, there was short interest totaling 15,008,738 shares, a drop of 22.4% from the February 26th total of 19,343,010 shares. Based on an average trading volume of 1,813,075 shares,
businesswire.com
Mar 26
Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced additional details for its Investor & Analyst Day in New York on April 22, 2026. Presentations and live question and answer sessions will be led by members of Definium's executive leadership team and external key opinion leaders who wi.